Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certican-based immunosuppression versus standard regimen in de novo kidney transplant patients
2011-005238-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2012
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, cyclosporine, tacrolimus and mycophenolic acid in kidney transplant and immunocompromise (3 arms), sponsored by Novartis. Primary endpoint: Renal function at month 12. Started Mar 2012; status: completed.
02
Drugs
everolimuscyclosporinetacrolimusmycophenolic acid
03
Conditions
kidney transplantimmunocompromise
Beyond the preview
Go deeper on 2011-005238-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005238-21.